Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders

IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY
Ekaterini Tiligada , Charikleia Stefanaki , Madeleine Ennis , Detlef Neumann
{"title":"Opportunities and challenges in the therapeutic exploitation of histamine and histamine receptor pharmacology in inflammation-driven disorders","authors":"Ekaterini Tiligada ,&nbsp;Charikleia Stefanaki ,&nbsp;Madeleine Ennis ,&nbsp;Detlef Neumann","doi":"10.1016/j.pharmthera.2024.108722","DOIUrl":null,"url":null,"abstract":"<div><div>Inflammation-driven diseases encompass a wide array of pathological conditions characterised by immune system dysregulation leading to tissue damage and dysfunction. Among the myriad of mediators involved in the regulation of inflammation, histamine has emerged as a key modulatory player. Histamine elicits its actions through four rhodopsin-like G-protein-coupled receptors (GPCRs), named chronologically in order of discovery as histamine H<sub>1</sub>, H<sub>2</sub>, H<sub>3</sub> and H<sub>4</sub> receptors (H<sub>1</sub><sub>–</sub><sub>4</sub>R). The relatively low affinity H<sub>1</sub>R and H<sub>2</sub>R play pivotal roles in mediating allergic inflammation and gastric acid secretion, respectively, whereas the high affinity H<sub>3</sub>R and H<sub>4</sub>R are primarily linked to neurotransmission and immunomodulation, respectively. Importantly, however, besides the H<sub>4</sub>R, both H<sub>1</sub>R and H<sub>2</sub>R are also crucial in driving immune responses, the H<sub>2</sub>R tending to promote yet ill-defined and unexploited suppressive, protective and/or resolving processes. The modulatory action of histamine <em>via</em> its receptors on inflammatory cells is described in detail. The potential therapeutic value of the most recently discovered H<sub>4</sub>R in inflammatory disorders is illustrated <em>via</em> a selection of preclinical models. The clinical trials with antagonists of this receptor are discussed and possible reasons for their lack of success described.</div></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"263 ","pages":"Article 108722"},"PeriodicalIF":12.0000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725824001426","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammation-driven diseases encompass a wide array of pathological conditions characterised by immune system dysregulation leading to tissue damage and dysfunction. Among the myriad of mediators involved in the regulation of inflammation, histamine has emerged as a key modulatory player. Histamine elicits its actions through four rhodopsin-like G-protein-coupled receptors (GPCRs), named chronologically in order of discovery as histamine H1, H2, H3 and H4 receptors (H14R). The relatively low affinity H1R and H2R play pivotal roles in mediating allergic inflammation and gastric acid secretion, respectively, whereas the high affinity H3R and H4R are primarily linked to neurotransmission and immunomodulation, respectively. Importantly, however, besides the H4R, both H1R and H2R are also crucial in driving immune responses, the H2R tending to promote yet ill-defined and unexploited suppressive, protective and/or resolving processes. The modulatory action of histamine via its receptors on inflammatory cells is described in detail. The potential therapeutic value of the most recently discovered H4R in inflammatory disorders is illustrated via a selection of preclinical models. The clinical trials with antagonists of this receptor are discussed and possible reasons for their lack of success described.
利用组胺和组胺受体药理学治疗炎症引起的疾病的机遇与挑战。
炎症驱动的疾病包括一系列病理状况,其特点是免疫系统失调导致组织损伤和功能障碍。在众多参与炎症调节的介质中,组胺已成为一个关键的调节因子。组胺通过四种类似于视黄醛的 G 蛋白偶联受体(GPCR)发挥作用,这四种受体按发现的时间顺序被命名为组胺 H1、H2、H3 和 H4 受体(H1-4R)。亲和力相对较低的 H1R 和 H2R 分别在介导过敏性炎症和胃酸分泌方面发挥关键作用,而亲和力较高的 H3R 和 H4R 则分别主要与神经传递和免疫调节有关。然而,重要的是,除了 H4R 外,H1R 和 H2R 也是驱动免疫反应的关键因素,其中 H2R 倾向于促进尚未明确和开发的抑制、保护和/或解决过程。本文详细介绍了组胺通过其受体对炎症细胞的调节作用。通过一些临床前模型,说明了最近发现的 H4R 在炎症性疾病中的潜在治疗价值。此外,还讨论了使用该受体拮抗剂进行的临床试验,并阐述了试验不成功的可能原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
23.00
自引率
0.70%
发文量
222
审稿时长
90 days
期刊介绍: Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信